Food and Drug Administration, HHS

preparation for 2 or 3 days, consult a veterinarian. Treatment should continue 24 to 48 hours beyond remission of disease symptoms, but not to exceed a total of 14 consecutive days. Discontinue treatment prior to slaughter as follows: Cattle, 1 day; sheep, 2 days; swine and goats, 3 days.

- (2) Turkeys—(i) Amount. 10 mg/lb of body weight per day (22 mg/kg) for 5 days.
- (ii) *Indications for use*. For the control of mortality associated with *E. coli* susceptible to neomycin sulfate in growing turkeys.
- (iii) Limitations. Add to drinking water; not for use in liquid supplements. Prepare a fresh solution daily. If symptoms persist after using this preparation for 2 or 3 days, consult a veterinarian. Treatment should continue 24 to 48 hours beyond remission of disease symptoms, but not to exceed a total of 5 consecutive days.

[71 FR 56866, Sept. 28, 2006, as amended at 71 FR 68738, Nov. 28, 2006]

§ 520.1510 Nitenpyram tablets.

- (a) Specifications. Each tablet contains 11.4 or 57 milligrams (mg) nitenpyram.
- (b) Sponsor. See No. 058198 in \$510.600(c) of this chapter.
- (c) Special considerations. The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets as in paragraph (d)(1)(ii)(B) of this section shall be by or on the order of a licensed veterinarian.
- (d) Conditions of use—(1) Dogs—(i) Amount—(A) One 11.4-mg tablet for dogs weighing less than 25 pounds (lb) or one 57-mg tablet for dogs weighing more than 25 lb, as needed, for use as in paragraph (d)(1)(ii)(A) of this section.
- (B) One 11.4-mg tablet for dogs weighing less than 25 lb or one 57 mg tablet for dogs weighing more than 25 lbs, once or twice weekly, for use as in paragraph (d)(1)(ii)(B) of this section.
- (ii) *Indications for use*—(A) For the treatment of flea infestations on dogs and puppies 4 weeks of age and older and 2 lbs of body weight or greater.
- (B) The concurrent use of nitenpyram tablets as in paragraph (d)(1)(i)(B) of this section with either flavored lufenuron tablets as in §520.1288(c)(1) of this chapter or flavored milbemycin

- and lufenuron tablets as in §520.1446(d)(1) of this chapter is indicated to kill adult fleas and prevent flea eggs from hatching.
- (2) Cats—(i) Amount—(A) One 11.4-mg tablet, as needed, for use as in paragraph (d)(2)(ii)(A) of this section.
- (B) One 11.4-mg tablet, once or twice weekly, for use as in paragraph (d)(2)(ii)(B) of this section.
- (ii) *Indications for use*—(A) For the treatment of flea infestations on cats and kittens 4 weeks of age and older and 2 lbs of body weight or greater.
- (B) The concurrent use of nitenpyram tablets as in paragraph (d)(2)(i)(B) of this section with flavored lufenuron tablets as in §520.1288(c)(2) of this chapter is indicated to kill adult fleas and prevent flea eggs from hatching.

[68 FR 51906, Aug. 29, 2003]

§ 520.1615 Omeprazole.

- (a) Specifications. Each gram of paste contains 0.37 gram omeprazole.
- (b) Sponsor. See No. 050604 in \$510,600(c) of this chapter
- (c) Special considerations. When labeled for use as in paragraph (d)(2)(i) of this section, product labeling shall bear: "Federal law restricts this drug to use by or on the order of a licensed veterinarian."
- (d) Conditions of use in horses—(1) Amount—(i) For treatment of gastric ulcers, 1.8 milligrams per pound (mg/lb) of body weight (4 milligrams per kilogram (mg/kg)) once daily for 4 weeks. For prevention of recurrence of gastric ulcers, 0.9 mg/lb of body weight (2 mg/kg) once daily for at least an additional 4 weeks.
- (ii) For prevention of gastric ulcers using the premarked syringe, one dose per day for 8 or 28 days. Each dose delivers at least 1 mg/kg of body weight. Horses over 1,200 lb body weight should receive two doses per day.
- (2) Indications for use. (i) For treatment and prevention of recurrence of gastric ulcers in horses and foals 4 weeks of age and older.
- (ii) For prevention of gastric ulcers in horses.
- (3) *Limitations*. Do not use in horses intended for human consumption.
- [69 FR 13220, Mar. 22, 2004, as amended at 71 FR 59374, Oct. 10, 2006]